Table 2.
Factors Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection Acquired Between 1 January and 31 October 2022 Among 489 Participants in the AGEhIV Coronavirus Disease 2019 Substudy
| Factor | Conditional Risk-Set Cox Proportion Hazards Model | |||
|---|---|---|---|---|
| Univariable | Multivariable | |||
| HR (95% CI) | P Value | aHR (95% CI) | P Value | |
| HIV status | ||||
| Negative | Reference | .11 | Reference | .28 |
| Positive | .86 (.71–1.04) | .89 (.73–1.09) | ||
| Smoking behaviora,b | ||||
| Never smoker | Reference | <.001 | Reference | <.001 |
| Former smoker | .80 (.65–.99) | .81 (.66–1.00) | ||
| Current smoker | .52 (.37–.73) | .51 (.36–.71) | ||
| Predicted anti-spike IgG titer by Luminex (per 1-log-unit increase)c,d | .46 (.33–.65) | <.001 | .45 (.32–.63) | <.001 |
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; IgG, immunoglobulin G.
aLast available data before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nuleocapsid antibody test.
bIn the last 6 months.
cLast known value before Omicron infection in participants with an Omicron infection or last known value in those without an Omicron infection.
dPredictions were obtained from a linear regression model whose parameter estimates are as follows: difference in mean anti-spike IgG titer relative to receipt of primary SARS-CoV-2 vaccination series alone, +0.25 (95% CI, .088–.41) for primary series plus 1 booster; +0.35 (.19–.51) for primary series plus 2 boosters; and +0.35 (.14–.55) for primary series plus 3 boosters (P <. 001).